DRG Epidemiology’s coverage of diabetic retinopathy (DR) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of DR for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s DR forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with DR?
Of all people with DR, how many in each major mature pharmaceutical market have been formally diagnosed?
Of all people diagnosed with DR, how many in each major mature pharmaceutical market are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DR over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following DR subpopulations:
Diagnosis status.
Treatment status.
Note: Coverage may vary by country and region.

Table of contents

  • Diabetic Retinopathy - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Total Prevalence of Diabetic Retinopathy per 1,000 People Aged 20+ in 2018 and 2028
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Diabetic Retinopathy over the Next Ten Years
      • Analysis of Total Prevalent Cases of Diabetic Retinopathy in 2018 by Severity
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases of DR
      • Total Prevalent Cases of DR by Severity
      • Diagnosed Prevalent Cases of DR
      • Drug-Treated Prevalent Cases of DR
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of DR
        • Studies Excluded from the Analysis of Diabetic Retinopathy
      • Risk/Protective Factors
        • Risk/Protective Factors for Diabetic Retinopathy
      • Bibliography

Author(s): Fjoralba Kristo, MD, MPH ; Nicole Zhang, MPH

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods.

Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.

Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders.

She holds an M.P.H. from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a B.A. in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.

Related Reports

Diabetic Macular Edema / Diabetic Retinopathy - Landscape & Forecast - Disease Landscape & Forecast

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and...

View Details

Diabetic Macular Edema | Diabetic Retinopathy | Disease Landscape and Forecast | G7 | 2020

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and blindness, especially with the development of diabetic...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030: Diagn...

View Details

Diabetic Macular Edema/Diabetic Retinopathy | Disease Landscape and Forecast | G7 | 2020

The DR / DME therapy market will grow moderately over the forecast period (6.6% annual growth through 2029); this growth will be due largely to: The launch of five new therapeuti...

View Details